Linder the Panerwork Reduction Act of 1995, no nersons are required t

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/570,734	
INFO	RMATION	DIS	CLOSURE	Filing Date	October 18, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Fernando Albericio Palomera	
				Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	Ronald T. Niebauer	
Sheet	1	of	2	Attorney Docket Number	13566.105010	

	•		U.S	. PATENT D	OCUME	NTS		
Examiner Initials *	Cite No. <sup>1</sup>	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US 6,274,551 US 2002/0164386	08-14-2001 11-07-2002		Scheuer Meisner			
	Cito	Foreign Patent Document	OREI	GN PATENT	DOCU	MENTS  Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind C ( <i>if known</i> )	ode <sup>5</sup>	Publication Date MM-DD-YYYY		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicants unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usoto.gov">www.usoto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 23). <sup>4</sup> For Japanese patent documents, be used to expert of the reign of the Emperor must precede the serial number of the patent document. <sup>8</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO Complete if Known Application Number 10/570,734 INFORMATION DISCLOSURE October 18, 2006 Filing Date STATEMENT BY APPLICANT First Named Inventor Fernando Albericio Palomera Art Unit 1654 (Use as many sheets as necessary) Examiner Name Ronald T. Niebauer 13566.105010 Sheet 2 of 2 Attorney Docket Number

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
		Angel Lopez i Macia, Ph.D. Thesis, Department de Quimica Organica. Facultat de Quimica Divisio de Ciencies Experimentals i Matematiques, Universitat de Barcelona, catalogued January 18, 2001				
		English translation: Angel Lopez i Macia, Ph.D., Thesis, Department de Quimica Organica. Facultat de Quimica Divisio de Ciencies Experimentals i Matematiques, Universitat de Barcelona, catalogued January 18, 2001, chapters 3,4 and Conclusion				
		Bertino et al., Principles of Cancer Therapy, Cecil Textbook of Medicine, vol. 1, pp. 1061-1074, 2000				
200000000000000000000000000000000000000	000000000000000000000000000000000000000	lose Carlos, limenez Garcia, Ph.D. Thesis, University of Barcelona, March 29	000000000000000000000000000000000000000			
		2004				
		Greaves et al., "Treatment of Psoriasis," The New England Journal of Medicine, 332(9), pages 581-588				
		Schellens et al., "Phase I and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Resistant Prostate Cancer," American Society of Clinical Oncology, May 18-21, 2002, vol. 21, part 1 of 2, p.113a				
		Schellens et al., "Phase I and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer," AACR-NCI-EORTC International Conference, 2001				
		Suggitt et al., "50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches," Clinical Cancer Research, vol. 11, February 1, 2005, pp. 971-981				

Examiner Signature	/Ronald Niebauer/	Date Considered	09/17/2009
-----------------------	-------------------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450**, Alexandria, VA 22313-1450.